2-(1,3-Diethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-N-methoxy-N-methyl-acetamide | 864513-52-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1,3-Diethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-N-methoxy-N-methyl-acetamide
• CAS: 864513-52-0
• 化学式: C₁₅H₂₁N₃O₃
• 分子量: 291.35
• InChiKey: KFIZJGMMRRAUBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.41
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  56.47
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  2-(1,3-Diethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-N-methoxy-N-methyl-acetamide 、 alkaline earth salt of/the/ methylsulfuric acid 以 四氢呋喃 为溶剂， 生成 1,3-Diethyl-5-[2-(4-fluoro-3-methyl-phenyl)-2-oxo-ethyl]-1,3-dihydro-benzoimidazol-2-one
  参考文献：
  名称：

  Benzimidazolone p38 inhibitors

  摘要：

  The synthesis and in vitro p38alpha activity of a novel series of benzimidazolone inhibitors is described. The p38alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.023
• 作为产物：
  描述：

  3,4-二氨基苯甲酸 在 lithium hydroxide 、 锂硼氢 、 sodium hydride 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 56.5h， 生成 2-(1,3-Diethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-N-methoxy-N-methyl-acetamide 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Benzimidazolone p38 inhibitors

  摘要：

  The synthesis and in vitro p38alpha activity of a novel series of benzimidazolone inhibitors is described. The p38alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.023